Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study

Area of Science:

• Neurology
• Immunology
• Medical Therapeutics

Background:

• Multiple sclerosis (MS) is a chronic, progressive neurological disease.
• Current treatments for severe, progressive MS have limited efficacy.
• Preliminary data suggested plasmapheresis might benefit MS patients.

Purpose of the Study:

• To evaluate the long-term efficacy of plasmapheresis combined with immunosuppressive therapy in severely progressive multiple sclerosis.
• To assess the impact of this combined treatment on disease progression and immune function.

Main Methods:

• Forty-five patients with severely progressive MS received long-term plasmapheresis, low-dose cyclophosphamide, and prednisone.
• Disease progression was monitored using the Kurtzke disability status scale (DSS), functional systems scale, neuro-ophthalmologic evaluations, evoked potentials, CT scans, and suppressor cell function assays.

Main Results:

• Significant clinical improvement was observed in 28 of 45 patients (62%).
• Limited improvement was noted in 14 patients (31%), with no change in 3 patients (7%).
• Improved suppressor cell function correlated with clinical improvement on the DSS.

Conclusions:

• Long-term plasmapheresis with cyclophosphamide and prednisone is a promising treatment for severely progressive multiple sclerosis.
• This therapeutic strategy may modulate immune function, contributing to clinical recovery.
• Further research is warranted to elucidate the mechanisms of action and long-term outcomes.